Q1FY24 Quarterly Result Announced for Marksans Pharma Ltd.
Pharmaceuticals company Marksans Pharma announced Q1FY24 results: Operating revenue was Rs 500.0 crore, up by 15.3% YoY driven by market share gains in the existing products and markets US business grew by +11.2% YoY UK and Europe grew by +24.8% YoY Gross profit was Rs 257.3 crore, up by +17.5% YoY with a Gross margin of 51.5%. EBITDA was Rs 102.0 crore, grew by 39.9% with an EBITDA margin of 20.4% EPS grew by 3.8% YoY to Rs 1.52 RoW business reported Rs 22.2 crore in Q1FY24 In Q1FY24, the capex incurred was Rs 81.5 crore Capex investment is in-line with our plan for scaling the acquired manufacturing unit from Teva Pharma in Goa Cash Balance at the end of June 30, 2023 is at Rs 636 crore in Q1FY24 In Q1FY24, Cash from Operations is at Rs 49.8 crore Result PDF14-08-2023
